Dr Brian Daniels is to retire from his role as senior VP, global development and medical affairs at Bristol-Myers Squibb (BMS) on July 1, 2014.
Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept). He took on his current role in 2008.
Francis Cuss, executive vice president and chief scientific officer, BMS said: "He has been a champion of the patients we serve, and I want to sincerely thank him for his loyalty and dedication to Bristol-Myers Squibb."
Prior to joining BMS, Dr Daniels spent four years at Merck Research Laboratories in clinical research where he ultimately assumed the role of senior director, pulmonary and immunology. He has also worked in clinical research at Genentech.
No results were found
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...